About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 72611 record(s)
Req # A-2022-001253
Adverse Drug Reactions (ADRs) for PANTOPRAZOLE SODIUM. Report numbers: E2B_05804048, E2B_05806287, E2B_05824479, E2B_05825410, E2B_05825749, E2B_05826892, E2B_05828141, E2B_05851183, E2B_05865879. ADR for PANTOPRAZOLE MAGNESIUM. Report number:…Organization: Health Canada
December 2023
Req # A-2022-001356
Adverse Drug Reactions (ADRs) for MESALAZINE. Report numbers: E2B_05926116, E2B_05879303, E2B_05951268, 001018724, 001018203, 001018211, 001017894. ADRs for MESALAMINE. Report numbers: E2B_05929118, E2B_05960176. ADR for TEDUGLUTIDE. Report number:…Organization: Health Canada
December 2023
Req # A-2023-000287
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-102700-258.Organization: Health Canada
December 2023
Req # A-2023-000422
Adverse Drug Reactions (ADRs). Report numbers: 001038537, E2B_05992367, E2B_06024320, E2B_06286365, E2B_03477995, E2B_03626645.Organization: Health Canada
December 2023
Req # A-2023-000462
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-075073-275.Organization: Health Canada
December 2023
Req # A-2023-000645
Adverse Drug Reactions (ADRs). Report numbers: E2B_06398091, 001047484, 001039932, 001041436, 001038654, E2B_06371725, E2B_06375154, E2B_06342155, 001042319, E2B_01948466.Organization: Health Canada
December 2023
Req # A-2023-000656
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-105904-169.Organization: Health Canada
December 2023
Req # A-2023-000675
Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_02229369, E2B_02381693, E2B_02396904, E2B_02504551, E2B_01438894, E2B_02504551, E2B_02381693, E2B_02760591, E2B_02511273, E2B_01497636.Organization: Health Canada
December 2023
Req # A-2023-000694
Adverse Drug Reactions (ADRs) for BREXPIPRAZOLE. Report numbers: E2B_06418076, E2B_06419341, E2B_06436667. ADRs for ABILIFY MAINTENA. Report numbers: E2B_06407071, E2B_06432983, E2B_06439726, E2B_06439727, E2B_06441940, E2B_06442211, E2B_06458876.Organization: Health Canada
December 2023
Req # A-2023-000700
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-104665-980.Organization: Health Canada
December 2023